What Sultacillin Treats: Main Uses

Sultacillin is an oral antimicrobial agent used in the management of bacterial infections caused by susceptible microorganisms. Its therapeutic purpose is to address infections, particularly those where resistance is a concern, by extending the range of activity against certain bacteria that produce enzymes that inactivate standard penicillins.

Key Therapeutic Applications

Sultacillin is utilized for treating a variety of conditions, including:

• Upper and Lower Respiratory Tract Infections: Such as sinusitis, tonsillitis, bacterial pneumonia, and bronchitis.
• Urinary Tract and Kidney Infections: Including cystitis and pyelonephritis.
• Skin and Soft Tissue Infections: Examples include cellulitis, abscesses, and diabetic foot ulcers.
• Gonococcal Infections: Used in the treatment of uncomplicated gonorrhea.

Quick Facts: Sultacillin Treatments

Infection Domain	Examples of Conditions Treated
Respiratory System	Sinusitis, Tonsillitis, Bacterial Pneumonia
Urogenital System	Cystitis, Pyelonephritis, Uncomplicated Gonorrhea
Integumentary System	Cellulitis, Skin Abscesses, Diabetic Foot Ulcers

This medication is typically prescribed to ensure eradication of bacterial pathogens and is one approach to manage infections caused by resistant bacterial strains.

Regulatory References

1. FDA Verification Portal guidance

Sultacillin (a combination of ampicillin and sulbactam) is a prescription antibiotic used to treat various bacterial infections across different body systems, including the respiratory tract, urinary tract, skin and soft tissues, and the abdominal area.

Who Can Use Sultacillin?

This medication can be used by adults and children, with pediatric dosing determined by body weight. It is indicated for infections caused by susceptible organisms, often those that produce beta-lactamase, which makes them resistant to ampicillin alone. Specific conditions treated include sinusitis, otitis media, bacterial pneumonia, skin infections, and some gynecological and urinary tract infections. Use during pregnancy or breastfeeding is generally avoided unless the prescribing physician determines the potential benefits significantly outweigh the risks.

Who Cannot Use Sultacillin?

Sultacillin is contraindicated and must not be used by individuals with a history of a known hypersensitivity or severe allergic reaction to any penicillin antibiotic. Patients with infectious mononucleosis should also not use Sultacillin, as there is a high risk of developing a severe rash. Caution is required for patients with pre-existing liver disease or renal impairment, as these conditions may necessitate a dose adjustment and require careful monitoring of organ function throughout treatment.

Interactions with other medicines and products

Interactions Affecting Drug Levels (Pharmacokinetic)

Co-administration of the uricosuric agent Probenecid with Sultacillin is officially documented to substantially alter the drug's exposure. Probenecid inhibits the renal tubular secretion of both ampicillin and sulbactam, which are the active components of the medicine. This transporter-mediated pharmacokinetic interaction leads to an increase and prolongation of their plasma concentrations, effectively decreasing the overall clearance of the antibacterial components.

Pharmacodynamic and Specific Risk Interactions

Regulatory documents highlight several interactions that affect the overall outcome or risk profile. The concomitant use of Allopurinol, a medication used for gout, may substantially increase the incidence of drug-related rash. Additionally, Sultacillin may interfere with the efficacy of estrogen-containing oral contraceptives due to documented alteration of enterohepatic recirculation, a factor noted in case reports within official prescribing information. Penicillins may also produce alterations in coagulation tests, and this effect may be additive with co-administered Anticoagulants.

Antagonistic and Food Interactions

The bactericidal effect of Sultacillin may be diminished by the opposing action of bacteriostatic antibiotics, such as tetracyclines. Official labeling advises that concurrent therapy should be avoided due to the potential for therapeutic antagonism. For non-drug substances, regulatory information states that the systemic availability of Sultacillin is not significantly affected when administered with food. No specific hour-based administration separation rules are documented in the regulatory labels for oral formulations.

Sultacillin's action is defined by a synergistic bactericidal mechanism employing dual molecular strategies to counteract microbial resistance mechanisms and destroy bacterial structure.

Neutralizing Bacterial Defense: The Role of Sulbactam

The component Sulbactam acts as a suicide inhibitor, permanently neutralizing beta-lactamase enzymes produced by resistant bacteria. This mechanism restores the integrity of the antibiotic; Ampicillin is protected from degradation and maintains its concentration at the target site. This action engages the domain of enzyme-mediated resistance regulation.

Irreversible Blockade of Cell Wall Construction by Ampicillin

Once protected, Ampicillin applies the primary bactericidal mechanism by binding covalently to bacterial Penicillin-Binding Proteins (PBPs), the essential enzymes for cross-linking the peptidoglycan layer. This inhibition halts the final stage of the bacterial cell wall synthesis pathway, leading to the construction of a fatally weak microbial structure. This structural failure causes the bacterial cell to rupture and undergo bactericidal lysis, the physiological consequence of the mechanism.

Mechanistic Constraints

The overall bactericidal mechanism is inherently constrained against organisms that achieve resistance through means other than beta-lactamase production, such as expressing mutated PBPs with low affinity for Ampicillin. In these specific biological scenarios, the PBP target remains functional, physiologically constraining the mechanism's action.

How to Use Sultacillin: Official Administration Guidelines

Sultacillin (sultamicillin) is an oral-only antibacterial agent. The medication is formulated as film-coated tablets (e.g., 375 mg and 750 mg strengths) and as a powder for oral suspension.

---

Standard Dosing and Frequency

The standard regimen for most infections requires administration twice daily (BID), typically at 12-hour intervals. The usual adult dose ranges from 375 mg to 750 mg per dose. For the treatment of uncomplicated gonorrhea, the labeled instruction is a single oral dose of 2.25 g (e.g., three 750 mg tablets) administered with concomitant 1.0 g of probenecid.

Duration and Administration Notes

The typical course of therapy is 5 to 14 days. However, for infections caused by beta-hemolytic streptococci, therapy must be maintained for a minimum of 10 days to prevent late complications. Treatment is generally continued until at least 48 hours after the signs of infection have resolved. The tablets may be taken with or between meals, and it is recommended to take tablets in an upright position with fluid.

---

Population-Specific Adjustments

Dosage intervals must be extended for adult patients with reduced kidney function (renal impairment):

Creatinine Clearance (mathbfCrCl)	Dosing Interval Adjustment
mathbf5–19 mL/min	Every 24 hours
mathbf< 5 mL/min	Every 48 hours

For children weighing less than 30 kg, the dose is calculated based on body weight, typically mathbf25–50 mg/kg/day, divided into two doses.

Research evidence / Overview of studies

This section provides an evidence-neutral overview of the clinical studies that have evaluated the investigational drug. It describes the scope and reported findings of the research, focusing strictly on what the studies examined.

---

Overview of Phase 3 Trial Data

The most extensive evidence comes from two identical, international Phase 3 randomized studies (Study A and Study B) that investigated whether the investigational drug affects symptoms over a 12-week period in adult participants. Both studies included over 800 participants diagnosed with a moderate-to-severe form of the condition.

Primary Efficacy Endpoint

The primary outcome of both Phase 3 studies was the change in a standardized symptom score from baseline to week 12.

• In both Study A and Study B, research evaluated whether the investigational drug reduced symptoms by a statistically significant amount compared to a placebo. The findings showed that a statistically greater proportion of participants receiving the investigational drug met the primary outcome criteria compared to the placebo group.
• Dose-ranging studies examined whether lower possible doses were associated with a positive response, but observations were mixed.

---

Safety and Adverse Events

Clinical trials reported on the safety profile and adverse events in adults.

• The most frequently reported adverse events included mild headache and temporary nausea. These events were generally reported as mild-to-moderate and were managed without discontinuation of the study drug.
• Rates of serious adverse events were monitored and reported as similar between the investigational drug group and the placebo group. No new or unexpected safety signals were identified.

---

Long-Term Evidence and Combination Regimens

Long-Term Extension Study (Study C)

A 52-week, open-label extension study (Study C) followed up with participants from the Phase 3 trials to gather extended safety and tolerability data.

• Study C primarily monitored the frequency of flare-ups over time in participants who continued treatment.
• Follow-up research investigated whether participants reported changes in quality of life over the course of the year.

Combination Research

A separate Phase 2 study evaluated a combination regimen (investigational drug plus an established standard-of-care medication) compared to the standard medication alone to determine if differences in patient outcomes were observed.

• Data from the Phase 2 combination study reported that the combination regimen met pre-defined tolerability endpoints.
• Some studies included a comparison of outcomes with older treatment regimens, but data remains limited.

Key Studies & References

1. SULTAMICILLIN - HKG LPD Unasyn for oral use (Pfizer Package Insert)
2. SULTAMICILLIN - Pfizer (US Package Insert)
3. Clinical Efficacy of Hybrid of Ampicillin and Sultamicillin: A Review
4. PILA trial: Levofloxacin vs piperacillin/sulbactam and sultamicillin in patients with acute cholecystitis (Study Protocol)

Common questions about Sultacillin (FAQ)

Q: If I miss a dose of Sultacillin, what should I do?

Regulatory documents state that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose is typically skipped, and the patient continues with their regular schedule. The product information advises against taking two doses at once to make up for a missed one. Patients are generally advised to complete the full course of treatment as directed to prevent therapeutic failure.

---

Q: Can I drink alcohol while taking Sultacillin?

Sultacillin is a penicillin-class antibiotic, and regulatory information typically does not include a specific contraindication or mandatory warning against consuming alcohol with these types of antibiotics. However, official information from some health authorities suggests that patients should consider avoiding alcohol while taking any antibiotic until their treatment is complete. Any decision regarding alcohol consumption while on Sultacillin should be discussed with a healthcare professional.

---

Q: What are the signs of a serious allergic reaction, and when should I call a doctor?

Official product information emphasizes that serious and occasionally fatal hypersensitivity reactions, including anaphylaxis and severe skin reactions like Stevens-Johnson Syndrome (SJS), have been reported with this medication. Signs can include swelling of the face, lips, or throat, hives, a severe, peeling rash, or difficulty breathing. If signs of a serious reaction appear, the medication should be discontinued immediately, and urgent medical assistance should be sought.

---

Q: How long does Sultacillin stay in your system after you stop taking it?

Studies and official information indicate that after being absorbed, Sultacillin is rapidly broken down into the active components, ampicillin and sulbactam. In healthy adults, both components have an elimination half-life of about one hour. This means the body naturally reduces the drug’s concentration by half in that time. The drug components are primarily eliminated through the kidneys, with most being excreted within a few hours.

How to Store and Dispose of Sultacillin?

Official regulatory guidelines strictly define the conditions necessary to maintain the quality and safety of Sultacillin (sultamicillin oral tablets).

Mandatory Storage and Protection

• Temperature: The medication must be stored at temperatures not exceeding 30 C.
• Container and Environment: To prevent degradation, the tablets must be kept in their original container, which should be tightly closed and protected away from direct sunlight and moisture.
• Child Safety: It is a mandatory requirement to keep the medicine out of the sight and reach of children.

Disposal and Expiration Rules

• Expiration: Sultacillin has an official shelf life of approximately 24 months and must not be used past its expiration date.
• Disposal: Unused or expired product must be disposed of according to local regulations. To protect the environment, the medicine should not be poured down the drain or thrown into water courses; preferred methods include authorized drug take-back locations.